ArcticZymes Technologies — Capital/Financing Update 2016

Apr 1, 2016

ArcticZymes awarded funding from the Horizon2020 programme

(Tromsø 01. April 2016) Biotec Pharmacon ASA("Biotec",OSE: BIOTEC) is pleased to announce that ArcticZymes, a subsidiary of Biotec Pharmacon has received EUR 460.000 over the next four years in a project funded by the European Framework Programme for Research and Innovation, Horizon 2020.

"We are excited to participate in the new granted "Virus-X" EU Consortium. It will allowArcticZymes to expand its access to novel molecular enzymes via the bioprospecting of a wide diversity of viral genomes.", says Jethro Holter, Managing Director, ArcticZymes AS.

The project "Viral Metagenomics for Innovation Value" (Virus-X), is a large collaboration project between a total of 15 partners from European research institutes, universities and industry with a total budget of nearly 8 M€, funded under Horizon2020 – Research and InnovationAction (RIA). Viruses represent the largest reservoir of unknown genetic diversity on earth and the project aim to advance the understanding of viral ecosystems, diversity and virus-host interplay by DNA sequencing environmental libraries (metagenomes) from a number of different biotopes. The project is driven by the expected large innovation value and unique properties of viral gene products. Through an analysis and discovery pipeline, new enzymes for molecular biotechnology will be developed, and ArcticZymes is one of the industrial partners that will participate developing and bringing new viral enzymes to the market.

"This is a milestone and great achievement ofArcticZymes. This acknowledges ArcticZymes experience and knowledge as a leading enzyme company within in the EU system", say Svein Lien, CEO, Biotec PharmaconASA.

For additional information:

Børge Sørvoll, CFO +47 952 90187 borge.sorvoll@biotec.no

Jetro Holter, MD ArcticZymes +47 468 59146 jh@arcticzymes.com

About Biotec Pharmacon:

Biotec PharmaconASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel immunomodulating products, including Woulgan®, a premium priced product in the advanced wound care market.ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics.